Pipeline

Melius is developing two EcN::ttr product candidates that leverage our BioPersist™ platform. This first-in-class genetically modified microbial has several potential applications in humans and animals.

Human Product

Melius is investigating MMB-003 (an EcN::ttr strain) as an investigational product for potential use in ulcerative colitis in humans. Melius is currently pursuing regulatory authorization to initiate a first-in-human clinical trial to evaluate safety and tolerability.

Pig Product

An EcN::ttr strain is also being tested as a feed additive for the pork industry to reduce mortality, improve feed efficiency, and increase weight gain. Melius has assessed safety and efficacy of EcN::ttr in mature pigs, and now planning trials in weaned pigs.